Sonnet Biotherapeutics Holdings Inc (SONN) - News Archive

Unveiling Innovative Treatments: Sonnet BioTherapeutics Promising Trials for Ovarian Cancer and Chemotherapy-Induced Peripheral NeuropathyIn the ever-evolving landscape of biopharmaceuticals, companies continuously stri...

A Legacy of Innovation: Sonnet BioTherapeutics Mourns Founder and CEO Pankaj Mohan, Ph.D. while Steering Forward Amid ChallengesPRINCETON, N.J. April 1, 2025 – In a profound moment of tragedy, Sonnet BioTherapeutics Hol...

Advancements in Immunotherapy: Sonnet BioTherapeutics Promising Developments and Patent Innovations Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biopharmaceutical company at the forefront of developing innovat...

Innovative Approaches to Pancreatic Cancer Treatment: Sonnet BioTherapeutics SON-1210 Clinical CollaborationIn the ongoing battle against one of the deadliest forms of cancer, pancreatic cancer remains a formidable chal...

In a recent announcement, Sonnet BioTherapeutics Holdings, Inc. revealed encouraging data from the Phase 1b portion of its Phase 1b/2a clinical trial evaluating SON-080 for the treatment of chemotherapy-induced peripher...

Sonnet BioTherapeutics Raises $3.4 Million in Gross Proceeds through Exercise of WarrantsSonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has announced the exercise of certain outstanding warrants for the immediate p...

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a company at the forefront of developing innovative targeted biologic drugs, has recently made a significant announcement. The company revealed that its ongoing SB22...